Our results indicated that these genes' (TP53, TTN, MUC16, RYR2, CSMD3, USH2A, LRP1B, ZFHX4, SYNE1, and XIRP2) mutations are frequently present in clinical lung cancer patients (Figure 4(a)). This evidence concerns the gene ZFHX4 and lung cancer.